Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Orient EuroPharma Co., Ltd. (4120:TWSE), powered by AI.
Orient EuroPharma Co., Ltd. is currently trading at $45.40. View real-time AI analysis on Alpha Lenz.
View the latest insider trading data for Orient EuroPharma Co., Ltd. on Alpha Lenz.
View Orient EuroPharma Co., Ltd.'s valuation metrics on Alpha Lenz.
“Orient EuroPharma Co., Ltd.'s ROE is -9.9%. Explore profitability and growth together.”
Ask for details →Orient EuroPharma Co., Ltd. is a publicly listed healthcare company specializing in the manufacturing and distribution of pharmaceuticals, health foods, and cosmetics. Established in 1982 and headquartered in Taipei, it operates primarily within the health technology sector, with a focus on the major pharmaceuticals industry. The company’s operations are divided into two main segments: the Western Medicine Section, which has demonstrated consistent revenue growth, and the Nutrition and Health Sector, which addresses consumer wellness trends and dietary supplementation needs. Orient EuroPharma’s product footprint spans key markets in Taiwan, Southeast Asia, and China, illustrating its regional influence and diversified revenue streams. The company serves hospitals, pharmacies, and health retail channels, liaising closely with healthcare professionals. Despite operating in a highly competitive landscape marked by regulatory scrutiny and rapid innovation, Orient EuroPharma maintains a significant market presence supported by a broad product portfolio and strategic international expansion. Its contributions underpin advancements in patient care and health maintenance across several Asian markets, emphasizing both pharmaceutical rigor and consumer health awareness.
“Orient EuroPharma Co., Ltd.'s ROE is -9.9%. Explore profitability and growth together.”
Ask for details →Orient EuroPharma Co., Ltd. (ticker: 4120) is a company listed on TWSE in the Healthcare sector (Drug Manufacturers - Specialty & Generic).
The current price is 45.4 with a P/E ratio of -x and P/B of -x.
ROE is -9.91% and operating margin is -6.50%. Annual revenue is $4.6B.